Growing evidence that changes in cerebral BDNF levels and in the BDNF-TrkB signaling pathway may be involved in the etiopathogenesis of Alzheimer’s disease (AD) [4] has suggested that blood BDNF could be used as a biomarker for AD diagnosis, prognosis, and treatment monitoring. The gene discussed is BDNF; the disease is Alzheimer disease.